A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer

ID Number 13-0692

Principal Investigator(s)
Philip Friedlander

Department(s) or Division(s)
Hematology and Medical Oncology


The main purpose of this study is to see if this experimental drug is safe and whether it works to help people with advanced or metastatic basal cell carcinoma. The study drug, when used in a laboratory setting, blocks a chemical signaling process that seems to be involved in allowing many types of cancers to grow. For this reason the sponsor and investigator are interested in studying whether it has any effect on cancers in human beings. LY 2940680 is a drug that blocks a pathway in cells called the Hedgehog pathway. This pathway is active in several types of cancer including basal cell carcinoma and is felt to contribute to the cancer growing. In basal cell carcinoma (BCC) the majority have a change or mutation in part of the hedgehog pathway that causes the pathway to be active.

Your taking part in this study may help to answer the following research question(s):

  • How safe is the study drug (what are the side effects)?
  • How does the study drug affect biomarkers (tests done on cells to evaluate the normal functions, disease, and/or study drug effects)? These cells are from skin, tumor and mouth cell samples.

• Does LY2940680 help fight BCC that has spread (or has grown extensively in the area in which it started)?

Contact Information
(212) 824-7308
(212) 824-7309

Recruiting Patients: No